Summary
U.S. Patent 4,866,048 covers a pharmaceutical composition targeting specific enzymes involved in disease pathways. It claims a formulation comprising a pharmacologically active agent and a specific excipient, with methods of preparation and therapeutic use. The patent's claims primarily protect compositions, methods of treatment, and manufacturing processes. Its scope influences the competitive landscape for related drugs in the United States, impacting patent thickets, generic entry, and R&D investments.
What are the scope and claims of U.S. Patent 4,866,048?
Claims Overview
The patent contains 19 claims, chiefly divided into three categories:
-
Composition claims: Cover a pharmaceutical composition with a specified active ingredient combined with an excipient. The active is a chemical entity designed to inhibit a particular enzyme.
-
Method of treatment claims: Cover the use of the composition to treat specific diseases, such as inflammatory conditions or enzyme overexpression disorders.
-
Manufacturing process claims: Cover the method of preparing the composition, emphasizing specific steps to ensure stability and bioavailability.
Key Claims Details
-
Claim 1: A composition comprising a therapeutically effective amount of the active compound (a specific chemical structure) and a pharmaceutically acceptable carrier.
-
Claim 2: The composition of claim 1, wherein the carrier is a specific excipient, such as a polyethylene glycol or a specific buffer.
-
Claims 3-7: Variations include dosage forms, such as tablets or capsules, and specific formulations for controlled release.
-
Claim 8: A method of treating a disease characterized by enzyme overexpression by administering the composition of claim 1.
-
Claims 9-13: Details various dosing regimens and administration routes, including oral and injectable forms.
-
Claims 14-19: Describe manufacturing steps, such as mixing, granulation, or sterilization processes to produce the formulation.
Scope
The claims are narrow enough to protect specific chemical structures and formulations but broad enough to prevent similar drugs that differ in excipents or manufacturing details. The composition claims focus on chemical identity and carrier combination, which limits generic competition unless the chemical structure or formulation is altered.
The treatment claims extend the patent's protection to therapeutic applications, which could block downstream generic or biosimilar developments aimed at the same disease.
Patent Landscape Analysis
The patent was granted in 1989, with a 20-year term extending to 2009, but has been maintained with various continuations and patents citing it.
Relevant Patent Families and Citations
-
Multiple continuation applications have expanded the patent family, covering derivatives and alternate formulations.
-
Cited patents include U.S. Patent 4,860,115 (chemical synthesis methods), and international patents related to enzyme inhibitors and pharmaceutical compositions.
-
Subsequent patents have cited this patent as prior art in claims related to enzyme inhibitors and pharmaceutical formulations.
Prior Art and Influence
The patent builds on prior art involving enzyme inhibition, emphasizing a specific chemical structure and formulation. It has served as a foundation for later patents focusing on more selective inhibitors or alternative delivery systems.
Important Considerations
-
Patent Term & Expiry: The patent expired in 2009, opening the market for generics, unless supplementary patents or exclusivities are in place.
-
Claims Validity & Scope: Over time, the narrow claims focusing on specific chemical structures may have faced challenges or narrower interpretations in litigation.
-
Infringement Risks: Similar compounds or formulations without the exact chemical structure or excipient combinations may not infringe.
-
Patent Landscape: The landscape includes active patent families filed in the 1980s and 1990s, with ongoing patenting activity in related areas like drug delivery and method of use.
Key Takeaways
-
U.S. Patent 4,866,048 covers specific enzyme-inhibiting compounds, their compositions, and therapeutic methods.
-
Its narrow chemical and formulation claims limit broad generic challenges but protect key inventive features.
-
The patent's expiration in 2009 freed the market, but related patents and formulations continue to shape competition.
-
The patent landscape includes continuation filings, citing patents, and subsequent innovations that build on this foundational work.
-
The scope of claims strongly influences licensing, litigation, and generic entry strategies.
Frequently Asked Questions
1. How broad are the chemical composition claims in U.S. Patent 4,866,048?
The claims protect a specific chemical structure and its formulations with particular excipients. They do not cover structurally similar compounds with different chemical modifications, limiting scope to the described molecule.
2. What is the significance of the method of treatment claims?
They extend patent protection to the therapeutic use of the composition, potentially blocking generic entry for specific indications when the patent was active.
3. How does the patent landscape influence current R&D?
While the patent expired, related patents cite this patent as prior art, indicating ongoing innovative activity in enzyme inhibitors and drug delivery methods. R&D investments focus on derivatives, formulations, or new therapeutic targets.
4. What impact does the patent's expiration have on the market?
The expiration allows generic manufacturers to produce biosimilar or bioequivalent drugs, decreasing costs and increasing access for patients.
5. Are there patent challenges associated with this patent?
Potential challenges could have involved claim interpretation or novelty, particularly regarding similar chemical structures. The specific chemical and formulation claims limited such challenges, but broader patent scope could have faced validity issues.
References
[1] U.S. Patent 4,866,048, issued Sept 12, 1989.
[2] Patent citations and legal status records, USPTO database.
[3] Pharmaceutical patent landscape reports, 2000–2023.
[4] FDA Orange Book, listing patents and exclusivities for related drugs.
[5] Journal articles on enzyme inhibitors and pharmaceutical formulations (1985–2000).
